Cargando…

TIPS-08 ACTION: A RANDOMIZED PHASE 3 STUDY OF DORDAVIPRONE (ONC201) IN PATIENTS WITH NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA

BACKGROUND: H3 K27M-mutant diffuse midline glioma is a universally fatal malignancy primarily affecting children and young adults. While radiotherapy (RT) provides transient benefit, no effective systemic therapy is currently available and current standard of care is RT followed by monitoring. Dorda...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arrillaga-Romany, Isabel, Lassman, Andrew, McGovern, Susan, Mueller, Sabine, Nabors, Louis Burt, van den Bent, Martin, Vogelbaum, Michael, Allen, Joshua E, Melemed, Allen S, Tarapore, Rohinton, Wen, Patrick, Cloughsey, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Trials in Progress
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402351/ http://dx.doi.org/10.1093/noajnl/vdad070.139

Ejemplares similares

NEIM-08 MODELING COMPETITION BETWEEN SUBPOPULATIONS WITH VARIABLE DNA CONTENT IN RESOURCE LIMITED MICROENVIRONMENTS
por: Katira, Parag, et al.
Publicado: (2023)

OTHER-08 CONCORDANCE OF INTRAOPERATIVE DIAGNOSIS AND FINAL DIAGNOSIS IN NEUROPATHOLOGY: A SINGLE INSTITUTION EXPERIENCE.
por: Gakinya, Samuel, et al.
Publicado: (2023)

SYST-08 ROLE OF THE MICROBIOME IN BRAIN TUMORS
por: Omer, Mohammed
Publicado: (2023)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

DIPG-80. CLINICAL AND RADIOGRAPHIC RESPONSE TO ONC201 IN A PEDIATRIC PATIENT WITH A THALAMIC H3K27M AND BRAFV600E MUTANT DIFFUSE MIDLINE HIGH GRADE GLIOMA
por: Duke, Elizabeth, et al.
Publicado: (2020)

GLIOMA-08 INTRACRANIAL HIGH-GRADE GLIOMA MANAGEMENT IN COTE D’IVOIRE : ABOUT 19 COALIGATED CASES FROM MARCH 2019 TO JUNE 2021
por: Drogba, Landry, et al.
Publicado: (2023)

SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
por: Odia, Yazmin, et al.
Publicado: (2022)

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG
por: Gardner, Sharon, et al.
Publicado: (2020)

MDB-08. THYROID HORMONES INHIBIT MEDULLOBLASTOMA PROGRESSION THROUGH INDUCING TUMOR CELL DIFFERENTIATION
por: Yang, Zeng-jie, et al.
Publicado: (2023)

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
por: Arrillaga-Romany, Isabel, et al.
Publicado: (2017)

Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy
por: Gardner, Sharon L, et al.
Publicado: (2022)

Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor
por: Anderson, Peter M., et al.
Publicado: (2022)

SDPS-08 OSSEOUS METASTASES IN H3G34-MUTANT DIFFUSE HEMISPHERIC GLIOMAS
por: Yu, Nina, et al.
Publicado: (2023)

IMG-08. VOLUMETRIC MEASUREMENT OF TUMOR SIZE OUTPERFORMS STANDARD TWO-DIMENSIONAL METHOD IN EARLY PREDICTION OF TUMOR PROGRESSION IN PEDIATRIC GLIOMA
por: Khalili, Nastaran, et al.
Publicado: (2023)

EPEN-08. COMBINED PDGFR INHIBITOR AXITINIB AND RETINOID TRETINOIN DECREASES PROLIFERATION AND HIGH-RISK NEOPLASTIC SUBPOPULATION PROPORTIONS PFA EPENDYMOMA
por: Donson, Andrew, et al.
Publicado: (2023)

NEIM-13 THE PROGNOSTIC ROLE OF VENTRICULAR SIZE AND ITS DYNAMICS IN PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS
por: Le Rhun, Emilie, et al.
Publicado: (2023)

HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
por: Kawakibi, Abed Rahman, et al.
Publicado: (2020)

ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways
por: Ni, Xiao, et al.
Publicado: (2017)

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells
por: Amoroso, Francesca, et al.
Publicado: (2021)

ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
por: Prabhu, Varun Vijay, et al.
Publicado: (2020)

CLRM-07 RANO 2.0: PROPOSAL FOR AN UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
por: Wen, Patrick, et al.
Publicado: (2023)

XRT-07. LATE-ONSET LYMPHOPENIA DURING CRANIOSPINAL RADIATION IS ASSOCIATED WITH AN INCREASED RISK OF TUMOR RECURRENCE IN NEWLY-DIAGNOSED PEDIATRIC MEDULLOBLASTOMA
por: Lindsay, Holly, et al.
Publicado: (2023)

CLRM-08 TAILORING CLINICAL TRIALS TO INCREASE PATIENT ENGAGEMENT: IMPACT ON PATIENT-REPORTED OUTCOMES IN ONCOLOGY
por: Khakwani, Saima, et al.
Publicado: (2023)

LMAP-08 MULTI-INSTITUTIONAL CLINICAL OUTCOMES FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM GYNECOLOGIC MALIGNANCIES
por: Huang, Christina, et al.
Publicado: (2023)

TIPS-04 A RANDOMIZED, MULTI-INSTITUTIONAL PILOT STUDY TO EVALUATE THE MOLECULAR AND CELLULAR RESPONSE TO TREATMENT WITH NIVOLUMAB WITH EITHER ADJUVANT IPILIMUMAB OR RELATLIMAB IN ADULT PATIENTS WITH SURGICALLY RESECTABLE MELANOMA BRAIN METASTASES: ONGOING TRIAL
por: Pina, Yolanda, et al.
Publicado: (2023)

IMMU-08. SALVAGE IMMUNOTHERAPIES FOR REPLICATION REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMA FAILING ANTI-PD1 MONOTHERAPY: AN IRRDC REPORT
por: Das, Anirban, et al.
Publicado: (2023)

SPCR-08 ACADEMIC READINESS AMONG CHILDREN TREATED FOR BRAIN TUMORS IN INFANCY
por: Silverman, Melanie, et al.
Publicado: (2023)

SYST-03 PHASE 1B STUDY OF AVELUMAB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD) FROM EPITHELIAL CARCINOMAS: FINAL RESULTS AND MOLECULAR ANALYSES WITH SINGLE CELL RNA SEQUENCING
por: Pina, Yolanda, et al.
Publicado: (2023)

NEIM-14 PET/MRI DETECTS A RAPID DECREASE IN CEREBRAL BLOOD FLOW IN GLIOBLASTOMA FOLLOWING BEVACIZUMAB INFUSION
por: Thaw-Poon, Serena, et al.
Publicado: (2023)

NEIM-03 A GRADUAL INTEGRATION MODEL BASED ON MRI TO PREDICT MOLECULAR PROFILES IN PATIENTS WITH GLIOMA
por: Chen, Hongyu, et al.
Publicado: (2023)

NEIM-11 DEUTERIUM METABOLIC IMAGING (DMI) DETECTS A LARGER WARBURG EFFECT IN HIGH-GRADE BRAIN TUMORS AND IN IDH WILD TYPE GLIOMAS
por: Kim, Lauren, et al.
Publicado: (2023)

NEIM-15 AN EXCEPTION TO THE METASTATIC RULE: A NON-ENHANCING MIDBRAIN LESION DUE TO METASTATIC FIBROMYXOID SARCOMA WITH EXTENSIVEINFLAMMATORY INFILTRATE
por: Rogawski, David, et al.
Publicado: (2023)

NEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR(18)F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY
por: Kotecha, Rupesh, et al.
Publicado: (2023)

NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH(18)F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY
por: Rosa, Alonso La, et al.
Publicado: (2023)

NEIM-07 HARNESSING END-TO-END CLOUD-BASED WORKFLOWS AND MULTI-MODAL DATA ANALYTICS IN PEDIATRIC BRAIN TUMOR IMAGING AT THE CHILDREN’S BRAIN TUMOR NETWORK (CBTN)
por: Nabavizadeh, Ali, et al.
Publicado: (2023)

NEIM-12 PRE- AND POST-TREATMENT RADIOLOGIC FEATURES AND VOLUMETRIC CHANGES LINKED TO TREATMENT RESPONSE OF BRAIN METASTASES AFTER LASER INTERSTITIAL THERMAL THERAPY (LITT)
por: Sanvito, Francesco, et al.
Publicado: (2023)

NEIM-01 IMMUNOSUPPRESSION IN THE GLIOMA MICROENVIRONMENT: USING PET IMAGING TO HIGHLIGHT THE PRESENCE OF TIGIT
por: Frederico, Stephen, et al.
Publicado: (2023)

METASTASES-03 PREVALENCE AND CLINICAL SIGNIFICANCE OF UNSUSPECTED INTRACRANIAL FINDINGS IN PATIENTS UNDERGOING ONCOLOGICAL WHOLE BODY(18) F- FLUORODEOXYGLUCOSE (FDG) PET CT IMAGING.
por: Nyamieri, Diana Kerubo, et al.
Publicado: (2023)

MENINGIOMA-03 FUNCTIONAL OUTCOME AFTER SURGERY FOR INTRACRANIAL MENINGIOMA AT THE KENYATTA NATIONAL HOSPITAL
por: Kagasi, Travor, et al.
Publicado: (2023)

GLIOMA-12 GLIOSARCOMA: A SERIES OF FOUR CASES TREATED
por: Drogba, Landry, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uofei8rtphslbmpp51pks9orvl